Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial

Abstract Background Here we evaluated the feasibility, efficacy, tolerability, and treatment-mediated immune modulation of neoadjuvant everolimus plus letrozole versus chemotherapy in treating postmenopausal patients with ER-positive, HER2-negative breast cancer. Methods Postmenopausal women with ER...

Fuld beskrivelse

Bibliografiske detaljer

Principais autores:	Wei Wu, Jiewen Chen, Heran Deng, Liang Jin, Zhanghai He, Nanyan Rao, Yan Nie, Yandan Yao, Yaping Yang, Fengxi Su, Jieqiong Liu
Format:	Artigo
Sprog:	Inglês
Udgivet:	BMC 2021-07-01
Serier:	BMC Cancer
Fag:	Randomized neoadjuvant pilot trial Everolimus plus letrozole Fluorouracil Epirubicin and cyclophosphamide (FEC) ER-positive and HER2-negative breast cancer
Online adgang:	https://doi.org/10.1186/s12885-021-08612-y
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!